Join Growin Stock Community!

Capricor therapeutics, inc.CAPR.US Overview

US StockHealthcare
(No presentation for CAPR)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

CAPR AI Insights

CAPR Overall Performance

CAPR AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CAPR Recent Performance

-3.53%

Capricor therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

CAPR PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

CAPR Key Information

CAPR Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

CAPR Profile

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.

Price of CAPR

CAPR FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CAPR Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.79
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
136.51
PB Ratio
18.09
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-736.62%
Revenue Growth (YoY)
-52.08%
Profit Growth (YoY)
-52.08%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.79
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
136.51
PB Ratio
18.09
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-736.62%
Revenue Growth (YoY)
-52.08%
Profit Growth (YoY)
-52.08%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is CAPR's latest earnings report released?

    The most recent financial report for Capricor therapeutics, inc. (CAPR) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CAPR's short-term business performance and financial health. For the latest updates on CAPR's earnings releases, visit this page regularly.

  • How is CAPR's revenue growth?

    In the latest financial report, Capricor therapeutics, inc. (CAPR) announced revenue of 0, with a Year-Over-Year growth rate of -100%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does CAPR have?

    As of the end of the reporting period, Capricor therapeutics, inc. (CAPR) had total debt of 14.54M, with a debt ratio of 0.12. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does CAPR have?

    At the end of the period, Capricor therapeutics, inc. (CAPR) held Total Cash and Cash Equivalents of 19.51M, accounting for 0.15 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is CAPR's EPS continuing to grow?

    According to the past four quarterly reports, Capricor therapeutics, inc. (CAPR)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.54. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of CAPR?

    Capricor therapeutics, inc. (CAPR)'s Free Cash Flow (FCF) for the period is -23.7M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 102.52% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.